Successfully treating ultra-refractory glaucoma patients

Article

Examing endoscopic cyclophotocoagulation as a treatment for ultra-refractory glaucoma patients.

Key Points

High resistance rate in patients

IOP and visual acuity

Safety issues

Remarkable results

The results experienced in this cohort of patients were especially remarkable considering the poor prognosis associated with these refractory eyes. Historical norms indicate that the long-term success of tube implantation to be about 50%. A previously failed tube has a three-fold increase in the risk for failure. Tube implantation has a significant rate of serious complications. Further, the failure of a previous tube increases this risk of complications for subsequent tubes. Transcleral cyclophotocoagulation would be unthinkable in this desperate group of patients due to its high complication and low success rates along with the proclivity for visual loss.

ECP demonstrated a remarkable level of efficacy, while creating few difficulties in this challenging group of patients that otherwise would be faced with poor therapeutic options.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Osamah Saeedi, MD, MS, at ARVO 2024
Dr Nir Shoham Hazon, Director, Miramichi EyeNB Centre of Excellence, New Brunswick, Canada
© 2025 MJH Life Sciences

All rights reserved.